Skip to content
10-K

Annual Report

CYTOSORBENTS CORPORATION CTSO

0001104659-26-036451

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 62.23M sh
Shares Diluted FY 2025 · Dec 31, 2024 54.43M sh
Capex FY 2025 · Dec 31, 2025 $164K
Capex restated FY 2025 · Dec 31, 2024 $284K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$12.38M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$14.43M
Long Term Debt FY 2025 · Dec 31, 2025 $16.67M
Long Term Debt restated FY 2025 · Dec 31, 2024 $14M
Cash And Equivalents FY 2025 · Dec 31, 2025 $6.25M
Cash And Equivalents restated FY 2025 · Dec 31, 2024 $3.28M
Stockholders Equity FY 2025 · Dec 31, 2025 $5.9M
Stockholders Equity restated FY 2025 · Dec 31, 2024 $11.11M
Stockholders Equity restated FY 2025 · Dec 31, 2023 $23.48M
Current Liabilities FY 2025 · Dec 31, 2025 $9.71M
Current Liabilities restated FY 2025 · Dec 31, 2024 $9.83M
Total Liabilities FY 2025 · Dec 31, 2025 $38.28M
Total Liabilities restated FY 2025 · Dec 31, 2024 $36.27M
Current Assets FY 2025 · Dec 31, 2025 $20.63M
Current Assets restated FY 2025 · Dec 31, 2024 $21.6M
Total Assets FY 2025 · Dec 31, 2025 $44.18M
Total Assets restated FY 2025 · Dec 31, 2024 $47.37M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.13
Eps Diluted FY 2025 · Dec 31, 2024 −$0.38
Eps Basic FY 2025 · Dec 31, 2025 −$0.13
Eps Basic FY 2025 · Dec 31, 2024 −$0.38
Sga Expense FY 2025 · Dec 31, 2025 $35.65M
Sga Expense restated FY 2025 · Dec 31, 2024 $33.73M
Net Income FY 2025 · Dec 31, 2025 −$8.2M
Net Income restated FY 2025 · Dec 31, 2024 −$20.72M
Operating Income FY 2025 · Dec 31, 2025 −$14.75M
Operating Income restated FY 2025 · Dec 31, 2024 −$16.45M
Gross Profit FY 2025 · Dec 31, 2025 $26.49M
Gross Profit restated FY 2025 · Dec 31, 2024 $24.89M
Cost Of Revenue FY 2025 · Dec 31, 2025 $10.57M
Cost Of Revenue restated FY 2025 · Dec 31, 2024 $10.71M